IDEXX Laboratories, Inc. (IDXX) has been gaining attention as a potential investment opportunity, with a bullish thesis outlined by @MoneyShow. As of March 12th, IDXX’s share price was at $571.21, with trailing and forward P/E ratios of 45.91 and 42.02 respectively.
IDEXX is a leading developer, manufacturer, and distributor of products for the veterinary, livestock, and water testing industries. The company is well-positioned to benefit from the growing trend of increased spending on pet healthcare, as pet owners seek advanced care for their animals. This trend is expected to drive demand for veterinary diagnostics, which is a highly profitable segment for IDXX.
The company has a strong financial track record, with consistent earnings per share growth that ranks in the top 10% of all companies. In November 2025, IDXX reported earnings that exceeded Wall Street estimates and raised its full-year guidance, leading to a surge in its share price to an all-time high. The aging cohort of pets from the pandemic puppy boom is expected to further boost demand for veterinary services and diagnostic testing.
IDEXX’s share price has reflected its operational success, with a 60.4% gain over the past 52 weeks. This, combined with its resilient business model, recurring revenue streams, and favorable demographic trends in pet ownership, makes IDXX a compelling investment opportunity in the pet healthcare sector. The company’s outlook remains positive, offering investors the potential for both growth and consistent profitability.
In conclusion, IDXX Laboratories, Inc. presents a strong investment case for those looking to capitalize on the structural growth in veterinary diagnostics. With its solid financial performance, expanding addressable market, and positive industry trends, IDXX is a stock worth considering for investors seeking exposure to the pet healthcare sector.
